in

Europe to Dominate Coronavirus Testing Kits Market Size by 2026

Growing cases of COVID-19 disease across the globe to drive the growth of global coronavirus testing kits market.

According to TechSci Research report, Global Coronavirus Testing Kits Market By Type of Test (Molecular v/s Serological), By Use (Multiple Test v/s Single Test), By Full Test Time (5 Hours-12 Hours, 1 Hours-5 Hours, 15-60 Minutes, Less than 15 Minutes, 12 Hours-24Hours, More Than 1 Day), By Technology (RT-PCR, Rapid Diagnostic Test, ELISA Tests, Others), By Specimen Type (Nasopharyngeal specimen, Oropharyngeal specimen, Blood, Sputum, Others), By Mobility (Stationary v/s Mobile), By End Use (Public Health Labs, Hospitals, Private or Commercial Labs, Physician Labs, Others), By Region, Forecast & Opportunities, 2026, the global coronavirus testing kits market was valued at USD50697.36 million in 2020 on account of the increasing R&D activities related to the production of coronavirus testing kits by major companies and research laboratories around the globe.

Additionally, increasing funding and grants by various governments around the globe for the development of testing kits, so that they can identify each case and take necessary preventive measures, is expected to foster the market over the next few years. Moreover, the deployment of test kits at a massive scale for testing people is anticipated to spur the market. Furthermore, increasing healthcare spending and rising need to protect the population from the outbreak are propelling the growth of the market. However, the high cost of testing kits might hamper the growth of the market, especially in developing economies. Additionally, the non-availability and shortage of testing kits might hinder the growth of the market. Besides, it has been found that some testing kits are not that efficient, which is negatively impacting market growth.

Browse 247 Figures spread through 110 Pages and an in-depth TOC on “Global Coronavirus Testing Kits Market”

https://www.techsciresearch.com/report/coronavirus-testing-kits-market/4693.html

The global coronavirus testing kits market is segmented based on type of test, use, full test time, technology, specimen type, mobility, end use, company and region. Based on type, the market can be bifurcated into molecular and serological tests. The molecular type of test segment is expected to dominate the market during the forecast period since it looks for the signs of an active infection or symptom. The specimen collected from the nasopharyngeal route is taken and sent for testing. Additionally, the sample undergoes a PCR test to find out the presence of the virus’ genetic material. The PCR confirms the diagnosis of COVID-19 if it finds two genes of the SARS-COV-2 virus. Moreover, these tests are helpful in identifying the current cases of the COVID-19 disease.

The serological tests segment is expected to witness significant growth during the forecast years since these tests are done using blood samples and detect the antibodies produced by the body against the virus. Such antibodies are present in an individual who has just recovered from COVID-19. Further, these tests are helpful in determining patients with mild or no symptoms. Based on use, the market can be divided into single test and multiple test. The multiple testing kits segment is expected to witness significant growth in the market during the next five years since they are based on community testing and are a faster and reliable method of getting results within groups of people.

Additionally, they provide faster diagnosis, are accurate, and simple & convenient to use. Based on full test time, the market can be fragmented into 5 Hours-12 Hours, 1 Hours-5 Hours,15-60 Minutes, Less than 15 Minutes,12 Hours-24 Hours, More Than 1 Day. The 5-12 hours segment is expected to dominate the market since the most preferred mode for testing, RT-PCR, generally takes this much time for the diagnosis of COVID-19. The RT-PCR test is followed by gene fingerprinting which usually takes time. The 15-60 minutes segment is also expected to witness significant growth during the forecast years because California-based molecular diagnostics company, Cepheid, has developed a rapid coronavirus diagnostic test with a detection time of about 45 minutes and has got approval from the FDA.

Also, Abbott Laboratories has developed a rapid test that will take around 5 minutes to diagnose the disease. Based on specimen type, the market can be segregated into nasopharyngeal specimen, oropharyngeal specimen, blood, sputum, and others. The nasopharyngeal specimen type is expected to dominate the market since these are the two prominent regions where the coronavirus replicates and hence are preferred for taking the patient’s specimen or sample. Also, the blood specimen type segment is expected to grow rapidly during the forecast period on account of the availability and growing preference for antibody-based testing kits, since they provide faster diagnostics of the disease. Based on end use, the market can be grouped into public health labs, hospitals, private or commercial labs, physician labs, others. The public health labs segment is expected to dominate the market owing to the presence of sophisticated diagnostic and treatment facilities they provide.

Abbott Laboratories, Altona Diagnostics GmbH, Roche Holding AG, BioMedomics Inc., Getein Biotech Inc, Hangzhou Biotest Biotech Company Ltd., AmonMed Biotechnology Co. Ltd., Beijing Tigsun Diagnostics Co Ltd., CTK Biotech Inc., Hunan Lituo Biotechnology Co. Ltd., Vivacheck Labaratories Inc., Thermo Fisher Scientific Inc., Siemens AG, Seegene Technologies Inc., FastSense Diagnostics Pvt. Ltd., Quest Diagnostics Inc., Quidel Corporation, Becton Dickinson and Company, QIAGEN N.V., PerkinElmer Inc. and others are some of the leading players operating in the global coronavirus testing kits market.

The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in March 2020, Pune (India) based molecular diagnostic company, Mylab, became the first Indian company to have received the validation for its COVID-19 diagnostic test kits also known as the Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests by the Drug Controller of India, after the National Institute of Virology validated its test. Today, the company along with companies like Altona Diagnostics and Siemens is supplying diagnostic kits to the world.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4693

Customers can also request for 10% free customization on this report.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website:https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

This post was created with our nice and easy submission form. Create your post!

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

India Nachos Market to Grow at an Impressive CAGR until FY2027

How Clinical Research Coordinator (CRCS) can ensure Best Career